m6A RNA甲基化修饰在心血管疾病中的进展

doi:10.3969/j.issn.1004-583X.2023.08.012

摘要/Abstract

摘要：

心血管疾病(cardiovascular disease,CVD) 是全世界死亡的主要原因。研究表明表观遗传修饰在CVD的进展中起着重要作用。在几种已知的RNA修饰中,N6-甲基腺苷(N6-methyladenosine,m6A) RNA甲基化修饰是研究最多的 RNA表观转录组修饰,该过程是动态的、可逆的,在mRNA代谢和各种生物活动中起着至关重要的作用。在这篇综述中,我们描述了m6A甲基化的作用机制,总结了m6A甲基化在CVD中的作用,包括动脉粥样硬化、心肌梗死、心力衰竭和糖尿病相关CVD等。m6A甲基化及其调控因子有望成为CVD的治疗靶点。

关键词: 心血管疾病, m6A, 甲基化, 心肌疾病, 表观基因组学

中图分类号:

顾天舒, 梁雪, 蔡嘉庚, 李广平. m6A RNA甲基化修饰在心血管疾病中的进展[J]. 临床荟萃, 2023, 38(8): 743-748.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://huicui.hebmu.edu.cn/CN/10.3969/j.issn.1004-583X.2023.08.012

https://huicui.hebmu.edu.cn/CN/Y2023/V38/I8/743

参考文献 46

[1]	Zhang B, Jiang H, Dong Z, et al. The critical roles of m6A modification in metabolic abnormality and cardiovascular diseases[J]. Genes Dis, 2020, 8(6): 746-758.
[2]	Dominissini D, Moshitch-Moshkovitz S, Schwartz S, et al. Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq[J]. Nature, 2012, 485(7397): 201-206. doi: 10.1038/nature11112
[3]	Frye M, Harada BT, Behm M, et al. RNA modifications modulate gene expression during development[J]. Science, 2018, 361(6409): 1346-1349. doi: 10.1126/science.aau1646 pmid: 30262497
[4]	Kumari R, Ranjan P, Suleiman ZG, et al. mRNA modifications in cardiovascular biology and disease: With a focus on m6A modification[J]. Cardiovasc Res, 2022, 118(7): 1680-1692. doi: 10.1093/cvr/cvab160 URL
[5]	Zhang L, Hou C, Chen C, et al. The role of N 6-methyladenosine (m6A) modification in the regulation of circRNAs[J]. Mol Cancer, 2020, 19: 1-11. doi: 10.1186/s12943-019-1085-0
[6]	Zeng C, Huang W, Li Y, et al. Roles of METTL3 in cancer: Mechanisms and therapeutic targeting[J]. J Hematol Oncol, 2020, 13(1): 1-15. doi: 10.1186/s13045-019-0838-y
[7]	Zhao W, Qi X, Liu L, et al. Epigenetic regulation of m6A modifications in human cancer[J]. Mol Ther Nucleic Acids, 2020, 19: 405-412. doi: 10.1016/j.omtn.2019.11.022 URL
[8]	Chien CS, Li JY, Chien Y, et al. METTL3-dependent N6-methyladenosine RNA modification mediates the atherogenic inflammatory cascades in vascular endothelium[J]. Proc Natl Acad Sci U S A, 2021, 118(7): e2025070118.
[9]	Pendleton KE, Chen B, Liu K, et al. The U6 snRNA m6A methyltransferase METTL16 regulates SAM synthetase intron retention[J]. Cell, 2017, 169(5): 824-835. doi: S0092-8674(17)30530-5 pmid: 28525753
[10]	Yue Y, Liu J, Cui X, et al. VIRMA mediates preferential m6A mRNA methylation in 3'UTR and near stop codon and associates with alternative polyadenylation[J]. Cell Discov, 2018, 4: 10. doi: 10.1038/s41421-018-0019-0
[11]	Jiang X, Liu B, Nie Z, et al. The role of m6A modification in the biological functions and diseases[J]. Signal Transduct Target Ther, 2021, 6(1): 74. doi: 10.1038/s41392-020-00450-x
[12]	Wang T, Kong S, Tao M, et al. The potential role of RNA N6-methyladenosine in Cancer progression[J]. Mol Cancer, 2020, 19(1): 1-18. doi: 10.1186/s12943-019-1085-0
[13]	Shen D, Wang B, Gao Y, et al. Detailed resume of RNA m6A demethylases[J]. Acta Pharm Sin B, 2022, 12(5): 2193-2205. doi: 10.1016/j.apsb.2022.01.003 URL
[14]	Wei J, Liu F, Lu Z, et al. Differential m6A, m6Am, and m1A demethylation mediated by FTO in the cell nucleus and cytoplasm[J]. Mol Cell, 2018, 71(6): 973-985. doi: 10.1016/j.molcel.2018.08.011 URL
[15]	Zaccara S, Ries RJ, Jaffrey SR. Reading, writing and erasing mRNA methylation[J]. Nat Rev Mol Cell Biol, 2019, 20(10): 608-624.
[16]	Zhang X, Wei LH, Wang Y, et al. Structural insights into FTO’s catalytic mechanism for the demethylation of multiple RNA substrates[J]. Proc Natl Acad Sci U S A, 2019, 116(8): 2919-2924. doi: 10.1073/pnas.1820574116 URL
[17]	Yu F, Zhu AC, Liu S, et al. RBM33 is a unique m6A RNA-binding protein that regulates ALKBH5 demethylase activity and substrate selectivity[J]. Mol Cell, 2023, 83(12):2003-2019. doi: 10.1016/j.molcel.2023.05.010 URL
[18]	Deng X, Qing Y, Horne D, et al. The roles and implications of RNA m6A modification in cancer[J]. Nat Rev Clin Oncol, 2023: 1-20.
[19]	Zhou B, Liu C, Xu L, et al. N6‐Methyladenosine reader protein YT521‐B homology domain‐containing 2 suppresses liver steatosis by regulation of mRNA stability of lipogenic genes[J]. Hepatology, 2021, 73(1): 91-103. doi: 10.1002/hep.31220 URL
[20]	Zeng M, Dai X, Liang Z, et al. Critical roles of mRNA m6A modification and YTHDC2 expression for meiotic initiation and progression in female germ cells[J]. Gene, 2020, 753: 144810. doi: 10.1016/j.gene.2020.144810 URL
[21]	Gao S, Sun H, Chen K, et al. Depletion of m6A reader protein YTHDC1 induces dilated cardiomyopathy by abnormal splicing of Titin[J]. J Cell Mol Med, 2021, 25(23): 10879-10891. doi: 10.1111/jcmm.v25.23 URL
[22]	Liu N, Zhou K I, Parisien M, et al. N6-methyladenosine alters RNA structure to regulate binding of a low-complexity protein[J]. Nucleic Acids Res, 2017, 45(10): 6051-6063. doi: 10.1093/nar/gkx141 pmid: 28334903
[23]	Huang H, Weng H, Sun W, et al. Recognition of RNA N 6-methyladenosine by IGF2BP proteins enhances mRNA stability and translation[J]. Nat Cell Biol, 2018, 20(3): 285-295. doi: 10.1038/s41556-018-0045-z
[24]	Wu R, Li A, Sun B, et al. A novel m6A reader Prrc2a controls oligodendroglial specification and myelination[J]. Cell Res, 2019, 29(1): 23-41. doi: 10.1038/s41422-018-0113-8
[25]	Virani SS, Alonso A, Benjamin EJ, et al. Heart disease and stroke statistics—2020 update: A report from the American heart association[J]. Circulation, 2020, 141(9): e139-e596.
[26]	Fu J, Cui X, Zhang X, et al. The role of m6A ribonucleic acid modification in the occurrence of atherosclerosis[J]. Front Genet, 2021, 12: 733871. doi: 10.3389/fgene.2021.733871 URL
[27]	尹亮, 刘德敏, 谷国强. 长链非编码RNA与冠心病相关性研究进展[J]. 临床荟萃, 2021, 36(5):462-466.
[28]	Brown RA, Shantsila E, Varma C, et al. Current understanding of atherogenesis[J]. Am J Med, 2017, 130(3): 268-282. doi: S0002-9343(16)31196-2 pmid: 27888053
[29]	Khatana C, Saini NK, Chakrabarti S, et al. Mechanistic insights into the oxidized low-density lipoprotein-induced atherosclerosis[J]. Oxid Med Cell Longev, 2020, 2020: 5245308.
[30]	Dong G, Yu J, Shan G, et al. N6-Methyladenosine methyltransferase METTL3 promotes angiogenesis and atherosclerosis by upregulating the JAK2/STAT3 pathway via m6A reader IGF2BP1[J]. Front Cell Dev Biol, 2021, 9: 731810. doi: 10.3389/fcell.2021.731810 URL
[31]	Wang T, Sun X, Cui H, et al. The peptide compound urantide regulates collagen metabolism in atherosclerotic rat hearts and inhibits the JAK2/STAT3 pathway[J]. Mol Med Rep, 2020, 21(3): 1097-1106. doi: 10.3892/mmr.2020.10934 pmid: 32016456
[32]	He M, Martin M, Marin T, et al. Endothelial mechanobiology[J]. APL bioeng, 2020, 4(1): 010904. doi: 10.1063/1.5129563 URL
[33]	尹惠阳, 蔺雪峰, 韩轩茂. 蛋白激酶B通路、乙酰肝素酶、NADPH氧化酶在心肌缺血再灌注损伤中的作用及相互关系的研究进展[J]. 临床荟萃, 2022, 37(5):459-462.
[34]	Li Y, Ren S, Xia J, et al. EIF4A3-induced circ-BNIP3 aggravated hypoxia-induced injury of H9c2 cells by targeting miR-27a-3p/BNIP3[J]. Mol Ther Nucleic Acids, 2020, 19: 533-545. doi: 10.1016/j.omtn.2019.11.017 URL
[35]	Ke WL, Huang ZW, Peng CL, et al. M6a demethylase fto regulates the apoptosis and inflammation of cardiomyocytes via yap1 in ischemia-reperfusion injury[J]. Bioengineered, 2022, 13(3): 5443-5452. doi: 10.1080/21655979.2022.2030572 URL
[36]	Zhu H, Zhou H. Novel insight into the role of endoplasmic reticulum stress in the pathogenesis of myocardial ischemia-reperfusion injury[J]. Oxid Med Cell Longev, 2021, 2021:5529810.
[37]	Freundt JK, Frommeyer G, Wötzel F, et al. The transcription factor ATF4 promotes expression of cell stress genes and cardiomyocyte death in a cellular model of atrial fibrillation[J]. Biomed Res Int, 2018, 2018:3694362.
[38]	Wang J, Zhang J, Ma Y, et al. WTAP promotes myocardial ischemia/reperfusion injury by increasing endoplasmic reticulum stress via regulating m6A modification of ATF4 mRNA[J]. Aging (Albany NY), 2021, 13(8): 11135-11149.
[39]	Zhang QJ, He Y, Li Y, et al. Matricellular protein Cilp1 promotes myocardial fibrosis in response to myocardial infarction[J]. Circ Res, 2021, 129(11): 1021-1035. doi: 10.1161/CIRCRESAHA.121.319482 URL
[40]	Li XX, Mu B, Li X, et al. circCELF1 Inhibits Myocardial Fibrosis by Regulating the Expression of DKK2 Through FTO/m6A and miR-636[J]. J Cardiovasc Transl Res, 2022, 15(5): 998-1009. doi: 10.1007/s12265-022-10209-0
[41]	曹晶晶, 张英杰, 常丽娟. 心房颤动发病机制及相关生物标志物研究进展[J]. 临床荟萃, 2022, 37(10):946-949.
[42]	Gao XQ, Zhang YH, Liu F, et al. The piRNA CHAPIR regulates cardiac hypertrophy by controlling METTL3-dependent N 6-methyladenosine methylation of Parp10 mRNA[J]. Nat Cell Biol, 2020, 22(11): 1319-1331. doi: 10.1038/s41556-020-0576-y
[43]	Liu X, Zhang Z, Ruan J, et al. Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores[J]. Nature, 2016, 535(7610): 153-158. doi: 10.1038/nature18629
[44]	王文琦, 张涛. 司美格鲁肽对2型糖尿病合并冠心病患者心肌缺血总负荷及血清炎症因子的影响[J]. 临床荟萃, 2022, 37(11):996-1000.
[45]	Meng L, Lin H, Huang X, et al. METTL14 suppresses pyroptosis and diabetic cardiomyopathy by downregulating TINCR lncRNA[J]. Cell Death Dis, 2022, 13(1): 38. doi: 10.1038/s41419-021-04484-z pmid: 35013106
[46]	Ju W, Liu K, Ouyang S, et al. Changes in N6-methyladenosine modification modulate diabetic cardiomyopathy by reducing myocardial fibrosis and myocyte hypertrophy[J]. Front Cell Dev Biol, 2021, 9: 702579. doi: 10.3389/fcell.2021.702579 URL

m6A RNA甲基化修饰在心血管疾病中的进展

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 46

相关文章 15

编辑推荐

Metrics

本文评价

[1]	王宁, 李勇. 簇集蛋白在心血管疾病中的研究进展[J]. 临床荟萃, 2022, 37(9): 842-845.
[2]	张怡, 崔晓冉, 杨晓红. 单核细胞/高密度脂蛋白胆固醇比值在心血管疾病中研究进展[J]. 临床荟萃, 2022, 37(6): 551-555.
[3]	张磊, 娄海东, 智昱, 亓树莹. PCSK9抑制剂对动脉粥样硬化性心血管疾病有效性及安全性的meta分析[J]. 临床荟萃, 2022, 37(12): 1074-1080.
[4]	杨瑞, 刘宇宏. 类风湿关节炎患者血脂水平与心血管疾病风险相关研究进展[J]. 临床荟萃, 2022, 37(1): 92-96.
[5]	叶蒙蒙, 李旎, 徐国栋, 邵国丰. miR-361在心血管疾病的研究进展[J]. 临床荟萃, 2021, 36(9): 843-849.
[6]	卢昊阳, 卢家忠, 韩明锋, 吕新才, 张标, 戎成振, 贾蕾蕾, 潘强强, 马蕾蕾, 赵韧. 新型冠状病毒肺炎合并心血管疾病的临床治疗观察[J]. 临床荟萃, 2021, 36(3): 203-207.
[7]	简郭进, 张斌. 沙库巴曲缬沙坦在心血管疾病中的研究进展[J]. 临床荟萃, 2021, 36(11): 1041-1045.
[8]	梁欢1，刘建凤2. 盘点钠-葡萄糖协同转运蛋白2抑制剂临床研究新进展[J]. 临床荟萃, 2020, 35(9): 861-864.
[9]	年士艳a，冯磊b. 云南省元江县傣族、哈尼族和彝族心血管病相关生化指标的差异性研究[J]. 临床荟萃, 2020, 35(8): 689-692.
[10]	刘晓腾a, 张英a, 金凤表b, 刘慧卿a, 高宇b, 李青联a, 侯瑞田a. 成纤维细胞生长因子21在糖脂代谢及心血管疾病中的研究进展[J]. 临床荟萃, 2020, 35(5): 472-475.
[11]	张令霞，聂倩，郝志华，刘承浩，王忠丽，陈菲菲，刘焕欣. 室内外工作环境对心血管系统炎性标志物的影响[J]. 临床荟萃, 2020, 35(3): 224-227.
[12]	赵晓琴, 范耀东. 沙库巴曲缬沙坦在心血管疾病中的新进展[J]. 临床荟萃, 2020, 35(12): 1132-1136.
[13]	吴美美1，王虹1，孙雪1，肖双1. 血小板/淋巴细胞与心血管疾病的研究进展[J]. 临床荟萃, 2020, 35(1): 88-91.
[14]	仵菲斐，马杰. 淋巴瘤的去甲基化治疗[J]. 临床荟萃, 2019, 34(6): 485-488.
[15]	李祎，姚马慧，刘德敏，王倩，耿雪，崔炜. 脉搏波传导速度及踝肱指数对心血管病患者的预后价值[J]. 临床荟萃, 2019, 34(11): 986-990.